Aldeyra Therapeutics Inc. has expanded its novel reactive aldehyde species (RASP) modulator pipeline with the discovery and advancement of new RASP modulators for the treatment of inflammatory and metabolic diseases.
Atomwise Inc. reported the development and preclinical evaluation data of ATMW-DC, a novel orally available allosteric inhibitor of TYK2 developed using Atomwise’s drug discovery platform Atomnet, for the potential treatment of psoriatic inflammation.
Graviton Bioscience BV has divulged new Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of arteriosclerosis, cancer, idiopathic pulmonary fibrosis, metabolic syndrome, multiple sclerosis, psoriasis, scleroderma and uveitis, among others.
Systemic sclerosis is an autoimmune disorder characterized by inflammation, vasculopathy and fibrosis, mainly affecting internal organs and the skin. There is still a lack of therapies for SSc-induced skin fibrosis.
Enveda Biosciences (Enveda Therapeutics Inc.) has announced a new series B2 financing round of $55 million. The drug discovery and development company uses artificial intelligence (AI)-powered technologies to translate nature into new medicines.
Santa Ana Bio Inc. has emerged from stealth with $168 million in combined series A and B funding and a focus on developing targeted therapies for patients with autoimmune and inflammatory diseases.
A Caregen Co. Ltd. patent details new peptides acting as autophagy and phagocytosis inducers potentially useful for the treatment of hyperpigmentation.
Eli Lilly & Co. has patented aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of psoriasis, atopic dermatitis, ulcerative colitis, Crohn’s disease, graft-vs.-host disease, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.
Atopic dermatitis (AD) is a chronic and highly prevalent skin disorder with multifactorial pathogenesis that includes mast cell (MC) activation as one of the main players.
Several cancer types are treated with epidermal growth factor receptor (EGFR)-targeting agents (EGFR inhibitors), but this treatment is associated with dermal toxicity in up to 90% of cases, where 80% of cases have rash, among other issues. This skin toxicity is mainly driven by elevation of Staphylococcus aureus and the proinflammatory cytokine IL-36γ. Skin keratinocytes’ cutaneous immune defense is impaired by EGFR inhibitors.
RSS
